Physician profile
Mitchell Todd Williamson
NPI 1790786473
$1,674.06
in general payments reported to CMS, 2019-2025
33 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $268 · 2021: $290 · 2022: $183 · 2023: $185 · 2024: $154 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $217.03 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $175.91 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $106.60 | 2021-2025 | Nuplazid |
| Banner Life Sciences, LLC | $97.44 | 2021-2024 | |
| Sk Life Science, INC. | $89.66 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $82.32 | 2019-2020 | |
| Abbott Laboratories | $79.95 | 2019 | |
| Lundbeck LLC | $69.18 | 2020-2023 | Rexulti |
| Abbvie INC. | $65.06 | 2021-2025 | Botox |
| Lilly USA, LLC | $61.92 | 2020-2024 | Kisunla |
| Jazz Pharmaceuticals INC. | $47.37 | 2020-2025 | |
| Emd Serono, INC. | $44.64 | 2019-2020 | |
| Celgene Corporation | $40.97 | 2021-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $37.98 | 2019-2024 | Ultomiris |
| Merz Pharmaceuticals, LLC | $31.69 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $31.34 | 2024 | Vyvgart Hytrulo |
| Vertex Pharmaceuticals Incorporated | $31.03 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.64 | 2025 | Hyqvia |
| Neurocrine Biosciences, INC. | $28.35 | 2023 | Ingrezza, Ongentys |
| Janssen Pharmaceuticals, INC | $28.14 | 2022 | |
| Acorda Therapeutics, INC | $28.09 | 2019 | |
| Neurelis, INC. | $26.69 | 2021 | |
| Greenwich Biosciences, INC. | $26.67 | 2019 | |
| Kyowa Kirin, INC. | $24.56 | 2019-2020 | |
| Amylyx Pharmaceuticals, INC. | $23.32 | 2023 | Relyvrio |
| Catalyst Pharmaceuticals, INC. | $23.09 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.82 | 2025 | Austedo Xr |
| Amneal Pharmaceuticals LLC | $19.64 | 2025 | Crexont |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2020 | |
| Ucb, INC. | $18.88 | 2024 | Nayzilam |
| Pfizer INC. | $16.97 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $16.53 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.